Objectives. To assess trends in the use of sacral neuromodulation and to measure the magnitude of variation in its use across geographic regions. Methods. We used the State Ambulatory Surgery Database (SASD) from 2002 to 2009 from Florida to identify patients implanted with a neuromodulator. Age-and gender-adjusted rates of implantation were calculated by year and by geographic region, defined by the Hospital Service Area. The coefficient of variation was estimated to quantify the magnitude of variation for different time periods. Results. Adjusted rates of sacral neuromodulation increased significantly from 1.
Introduction
Sacral neuromodulation is a relatively new treatment that is used for multiple, different lower-urinary-tract conditions. It was approved by the US Food and Drug Administration in 1997 for treatment of urge urinary incontinence, in 1999 for treatment of urinary urgencyfrequency and nonobstructive urinary retention, 1 and in 2011 for fecal incontinence. 2 It has also been used to treat interstitial cystitis, 3 chronic pelvic pain, 4 neurogenic bladder symptoms, 5 and sexual dysfunction. 6 Since its introduction, more than 100 000 sacral neuromodulators have been implanted, 7 at a cost of nearly $2 billion. 8 Despite its growing use and popularity, relatively little is known about the dissemination of these devices in community practice. Clinical indications for sacral neuromodulation are not absolute and depend on the preferences of the physician and the patient. 9 In such a setting, decisions on whether or not to implant a neuromodulator are susceptible to a variety of nonclinical factors, including physician training, physician comfort with performing the procedure, patient desires and expectations, community norms regarding preferred treatments, and associated financial incentives. As a direct reflection of the uncertainty surrounding when and in whom to implant, physicians likely vary greatly in their use of sacral modulation.
To examine this issue more carefully, we performed a study to assess trends in implantation of sacral neuromodulators. We used population-based data and leveraged small-area variation methods to understand the scope of uncertainty surrounding the use of these devices.
Materials and Methods

Participants
This study used data from the State Ambulatory Surgery Database (SASD) from 2002 through 2009 from the state of Florida. 10 The SASD is maintained by the Healthcare Cost and Utilization Project (HCUP) and provides patient-level discharge data for all ambulatory procedures performed during this time period. We chose the state of Florida for 2 reasons. First, it is one of the larger and more ethnically diverse states participating in the Healthcare Cost and Utilization Project. Second, it captures discharges from a broad array of practice settings, including freestanding ambulatory surgery centers, where these procedures are commonly performed.
We identified patients aged 18 years and older who underwent insertion or replacement of peripheral neurostimulator pulse generator or receiver (Current Procedure Terminology [CPT] Code 64590] between 2002 and 2009. Only those patients undergoing final placement of the sacral neuromodulator were included. Test stimulation procedure phases (CPT codes 64561 or 64585) were not a part of this analysis.
ICD-9 (International Classification of Diseases, Ninth Edition) codes were used to characterize the clinical indications for the procedure. For this purpose, patients were first sorted into 1 of 5 mutually exclusive groups, including neurogenic bladder, interstitial cystitis, nonobstructive urinary retention, urgency incontinence, and dry overactive bladder, as previously described. 9 Collectively, these groups comprised 98.5% of all patients undergoing neuromodulator implantation. The remaining 74 patients (1.5%) were combined and categorized as an "other group."
Statistical Analysis
We used Poisson regression to estimate trends over time for rates of procedures, both overall and for the individual indications. Rates were adjusted for age and gender based on data from the US Census estimates for Florida. 11 To understand more about time trends, we performed a series of analytic procedures. First, we divided all patients into groups based on 4 time periods (2002-2003, 2004-2005, 2006-2007, and 2008-2009 ) and evaluated trends in diagnosis, gender, age, race, insurance, socioeconomic class, 12 and Charlson score 13 over time. Differences in these characteristics between time periods were estimated using the Mantel-Haenszel χ 2 statistic.
Second, we evaluated the extent of variation in rates of implantation between markets over time. Rates were calculated using the indirect method of adjustment for gender and age. We chose the indirect method, as opposed to the direct method, because of the small numbers of procedures in each age/gender category. To measure these local health care markets, we used the Hospital Service Area (HSA) as described by the Dartmouth Atlas. 14 Each HSA represents a collection of zip codes in which residents receive their hospital care. The state of Florida has 114 HSAs that range in size from 5000 to 190 000 inhabitants.
We assessed the magnitude of variation between HSAs using the coefficient of variation. The coefficient of variation is the ratio of the standard deviation of the rates to the mean rate. 15 This calculation gives an estimate of variation between geographic regions for a procedure that is standardized to both the population size and the frequency of the procedure. Thus, this value can be used as a means of comparing the amount of variation in rates between different procedures. Higher values of the coefficient of variation are indicative of more variation.
Third, we wanted to determine if patient characteristics differed among HSAs with high implantation rates versus those with low implantation rates. We suspected that patients in high-volume regions would reflect a more diverse group demographically and would demonstrate a wider variety of indications for the procedure. We looked specifically at rates in the years 2008-2009, which represented the majority (55.5%) of our cases. We divided HSAs into terciles (ie, equal number of markets) based on rates. We then contrasted demographic and clinical characteristics across the 3 groups of HSAs.
Analyses were performed with SAS version 9.3 (SAS Institute, Cary, NC). The probability of a type I error was set at .05, and all testing was 2 sided. The study was classified as exempt by our institutional review board.
Results
A total of 3857 patients underwent implantation of sacral neuromodulators between 2002 and 2009. During this time period, adjusted rates of these procedures increased from 1.1 per 100 000 population to 10.4 per 100 000 population (P < .001). As shown in Figure 1 , rates increased for all clinical indications (P < .001), except for interstitial cystitis (P = .379) and the "other" category (P = .293). Overactive bladder, both wet and dry, represented the largest group of patients. Table 1 . Patients who underwent these procedures in later years were more likely to be older and insured by Medicare. Additionally, patients tended to have more comorbid illnesses, as measured by a higher percentage of patients with a Charlson score of 2 or higher. We observed no significant differences in urological diagnosis, gender, race, or socioeconomic class over time.
Rates of sacral neuromodulator implantation for each HSA are shown in Figure 2 for each of the 4 time periods. As time advances, there are more HSAs performing these procedures and at higher rates. The median rates of procedures at the HSA level for each time period were 0.9 per 100 000 population (range 0-21. Finally, we wanted to determine whether there were differences in patients who underwent the procedure in high-volume HSAs as opposed to low-volume HSAs ( Table 2 ). High-volume HSAs were more likely perform the procedure on patients who were older, white, insured by Medicare, and of lower socioeconomic class. Clinical indication, gender, and Charlson score did not significantly differ between the 3 groups.
Discussion
Rates of sacral neuromodulator implantation increased by more than 9-fold in the state of Florida between 2002 and 2009. Although the relative distribution of clinical indications for the procedure evolved over time, overactive bladder was by far the most common reason for implantation. Adoption and utilization of this procedure were substantial during this time period, yielding significant variation across regions at the HSA level. Although the literature on sacral neuromodulation consists of numerous studies and clinical trials attesting to its safety and efficacy, 9, [16] [17] [18] [19] [20] [21] [22] this is the first study to describe its adoption in community practice. Given the medical uncertainty and discretion surrounding the indications for implantation, it is not surprising that we observed such widespread variation in rates of utilization.
It is interesting to note that we found that the use of sacral neuromodulation was dominated by a select few health care markets. In 2008 and 2009, only 5 HSAs performed more than 100 procedures. These HSAs accounted for more than a third (35.2%) of all procedures. Patients who underwent a procedure in these very high-volume HSAs tended to be the older, Medicare-insured population. One possible explanation is that providers in these markets are meeting a latent clinical demand. Alternatively, providers might be becoming more comfortable with the procedure and are, thereby expanding its indications to a larger patient population. In a similar context, it is possible that some markets may be underutilizing sacral neuromodulation. In 2008 and 2009, 13 HSAs did not perform any of these procedures, whereas 68 HSAs performed fewer than 20 procedures each.
It is difficult to determine the "appropriate" rate of sacral neuromodulator implantation. Although we do expect some degree of variability in rates between adjacent health care markets, the variation between regional rates observed in this study is striking. As of 2008 and 2009, the coefficient of variation, a standardized measure of variation, for procedure use was 1.05. To place this finding in context, it is useful to consider the coefficient of variation for other surgical procedures. Hip replacement, the rate of which is largely determined by the incidence of hip fracture, 23 has a coefficient of variation of 0.12, nearly one-tenth that of sacral neuromodulation. Values for other procedures include 0.13 for cholecystectomy, 0.26 for hysterectomy, and 0.45 for routine circumcision. 15 Collectively, these data suggest that, at least relative to these other procedures, there is considerable disagreement about who should and should not undergo this procedure.
It is also interesting to note that the observed rates of increase in the use of sacral neuromodulation, especially for overactive bladder, occurred during a time when several medications for this indication were released to the market. The significant growth of this surgical procedure in the face of these new drugs suggests that there is great dissatisfaction with these more "conservative" treatments for overactive bladder.
Our findings should be interpreted in the context of a few limitations. First, geographic data were calculated based on the residence address of each patient, rather than treatment location (ie, where the surgery was performed). As these procedures are elective and discretionary, we expect that the vast majority of patients undergo such procedures locally, so we do not view this as a significant issue. Additionally, any misclassification would be nondirectional and have minimal impact on our findings. Second, because of the nature of the data, it does not include those procedures done in the inpatient or office settings. We believe, however, that the majority of the final implantation procedures are performed in the ambulatory surgery setting. 9 Finally, some may worry about the generalizability of our findings beyond the state of Florida. As discussed earlier, we chose to use the state of Florida because it represents one of the most populated and diverse states represented by the HCUP. We found a large amount of variation in this state, and we have no strong reasons to believe that our findings would be different elsewhere.
Conclusion
Rates of sacral neuromodulation increased dramatically over the past decade. Growth in the use of this procedure was limited to a few health care markets. Generally speaking, regions appear to vary widely in their threshold for implanting sacral neuromodulators, as evidenced by the dramatic regional variation. Future research is needed to better determine who should and should not be candidates for use of this new technology. 
